Kenneth O'Byrne
肯尼思·奥伯恩
MB BCh BAO, PhD, FRCP
Professor of Thoracic Oncology; Director, Thoracic Oncology Research Group胸部肿瘤学教授；胸部肿瘤研究组主任
👥Biography 个人简介
Australia's most prominent thoracic oncologist, leading EGFR-targeted therapy trials at Princess Alexandra Hospital and serving as chief investigator on multiple national and international NSCLC studies. Expert in translational biomarker research integrating molecular pathology with clinical outcomes.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Australian EGFR TKI Trials
Led multiple EGFR-targeted therapy trials as national chief investigator in Australia, contributing to landmark international datasets on TKI efficacy and resistance in diverse patient populations.
Translational Biomarker Research
Pioneered integration of molecular pathology and genomic profiling into thoracic oncology clinical trials in Australia, bridging laboratory discoveries with patient outcomes in EGFR-mutant NSCLC.
Representative Works 代表性著作
Molecular Testing Pathways for NSCLC in the Era of Targeted Therapy: Australian Perspective
Journal of Thoracic Oncology (2020)
Comprehensive framework for EGFR and comprehensive molecular testing in Australian NSCLC practice, influencing national clinical guidelines.
EGFR Inhibitor Resistance Mechanisms in Advanced NSCLC: Clinical Implications
Annals of Oncology (2018)
Review of EGFR TKI resistance mechanisms with clinical management recommendations, widely cited in global thoracic oncology practice.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 肯尼思·奥伯恩 的研究动态
Follow Kenneth O'Byrne's research updates
留下邮箱，当我们发布与 Kenneth O'Byrne（Princess Alexandra Hospital, University of Queensland）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment